Oxford Instruments (OXIG) H2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2026 earnings summary
9 Jun, 2026Executive summary
Achieved strong full-year performance with significant improvement in the second half, overcoming early market headwinds and delivering results ahead of expectations.
Orders grew 8% year-over-year to £450.4m, with revenue at £423.2m, down 3% on an organic constant currency basis.
Strategic transformation included divesting the NanoScience business, simplifying operations into two divisions, and focusing on commercial and high-volume manufacturing customers.
Operational execution and restructuring, especially in Belfast, drove margin improvement, cost efficiencies, and a 60% productivity gain.
Positioned for further growth in FY 2027, with a robust order book and strong momentum in key markets.
Financial highlights
Group gross margin increased to 55.8%, up 90 basis points year-over-year on a constant currency basis.
Revenue declined 3% year-over-year at constant currency, but recovered in Q4/H2, especially in Advanced Technologies.
Cash conversion remained strong at 89%, with robust free cash flow of £41.9m despite lower operating profit.
Adjusted operating margin improved to 18.2% after NanoScience divestment, up 150 basis points.
Adjusted EPS fell 7.7% to 100.7p; full-year dividend up 6.3% to 23.6p.
Outlook and guidance
Expecting strong H1 FY27 revenue growth as order backlog converts, with high teens revenue growth in Advanced Technologies and margin targets raised to 12%-15% medium term.
Imaging & Analysis anticipated to deliver low single-digit revenue growth in FY 2027.
Order book at year-end covers the majority of FY 2027 revenue expectations, supporting strong execution focus.
Adjusted tax rate expected to stabilize at 24%-24.5% in FY 2027, about 100 basis points below previous guidance.
Latest events from Oxford Instruments
- Strong order growth and resilient H2 performance support a positive outlook for the next year.OXIG
Q4 2026 TU14 Apr 2026 - Revenue up 9.8%, margin target above 20%, with strong growth and strategic transformation.OXIG
H2 202423 Feb 2026 - Strong order growth and capital actions support full-year profit outlook.OXIG
Q3 2026 TU15 Jan 2026 - Strong 10.4% revenue growth and robust order book drive positive full-year outlook.OXIG
H1 202515 Jan 2026 - Order recovery and cost actions set stage for stronger H2 after a challenging first half.OXIG
H1 202616 Dec 2025 - Record revenue, margin expansion, and NanoScience divestment drive strong outlook.OXIG
H2 202514 Nov 2025 - H1 order intake rose 1% OCC, but revenues fell 8% OCC; full-year outlook remains stable.OXIG
H1 2026 TU13 Oct 2025 - Revenue up 10% at constant currency, but currency headwinds to impact reported profit.OXIG
Trading Update13 Jun 2025 - Strong revenue and margin growth driven by robust divisional performance and strategic execution.OXIG
Trading Update6 Jun 2025